Base de dados : MEDLINE
Pesquisa : D02.540.576.500.500 [Categoria DeCS]
Referências encontradas : 13923 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1393 ir para página                         

  1 / 13923 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28458494
[Au] Autor:Sahota R; Gambhir R; Anand S; Dixit A
[Ad] Endereço:Department of Oral Pathology, Rayat and Bahra Dental College and Hospital, Mohali.
[Ti] Título:Rhinocerebral Mucormycosis: Report of a Rare Case.
[So] Source:Ethiop J Health Sci;27(1):85-90, 2017 Jan.
[Is] ISSN:2413-7170
[Cp] País de publicação:Ethiopia
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Mucormycosis is one of the rapidly progressing and lethal form of fungal infection which involves the nose and paranasal sinuses of the head and the neck regions. Mucormycosis also remains a threat to patients with uncontrolled diabetes or other predisposing systemic conditions. It manifests as rhinocerebral, pulmonary, gastrointestinal, cutaneous or disseminated form. The underlying conditions can influence clinical presentation and often delay diagnosis, with resultant poor outcomes. CASE DETAILS: We report a case of rhinocerebral mucormycosis in a 75 year-old diabetic patient with emphasise on diagnosis, treatment and survival options of patient from this potentially fatal fungal infection. Extra oral examination revealed mild non-tender swelling on the face, unable to see from left eye, impaired sense of smell, difficulty in speech and nasal stuffiness. Intra-oral examination showed necrosis of mucosa and underlying bone in relation to canine to the tuberosity area of the left vestibular region of the maxilla. CONCLUSION: Timely diagnosis is critical to survival and minimization of morbidity. Institution of surgical and medical therapy is critical in maximizing the likelihood of good outcome.
[Mh] Termos MeSH primário: Antifúngicos/uso terapêutico
Mucormicose/diagnóstico por imagem
Mucormicose/tratamento farmacológico
Seios Paranasais/diagnóstico por imagem
[Mh] Termos MeSH secundário: Idoso
Anfotericina B/uso terapêutico
Seres Humanos
Masculino
Mucormicose/cirurgia
Necrose
Seios Paranasais/patologia
Seios Paranasais/cirurgia
Tomografia Computadorizada por Raios X/métodos
Triazóis/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Triazoles); 6TK1G07BHZ (posaconazole); 7XU7A7DROE (Amphotericin B)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  2 / 13923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29326050
[Au] Autor:Nayak A; Akpunarlieva S; Barrett M; Burchmore R
[Ad] Endereço:Institute of Infection, Immunity and Inflammation and Glasgow Polyomics, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
[Ti] Título:A defined medium for Leishmania culture allows definition of essential amino acids.
[So] Source:Exp Parasitol;185:39-52, 2018 Feb.
[Is] ISSN:1090-2449
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Axenic culture of Leishmania is generally performed in rich, serum-supplemented media which sustain robust growth over multiple passages. The use of such undefined media, however, obscures proteomic analyses and confounds the study of metabolism. We have established a simple, defined culture medium that supports the sustained growth of promastigotes over multiple passages and which yields parasites that have similar infectivity to macrophages to parasites grown in a conventional semi-defined medium. We have exploited this medium to investigate the amino acid requirements of promastigotes in culture and have found that phenylalanine, tryptophan, arginine, leucine, lysine and valine are essential for viability in culture. Most of the 20 proteogenic amino acids promote growth of Leishmania promastigotes, with the exception of alanine, asparagine, and glycine. This defined medium will be useful for further studies of promastigote substrate requirements, and will facilitate future proteomic and metabolomic analyses.
[Mh] Termos MeSH primário: Aminoácidos Essenciais/metabolismo
Meios de Cultura/química
Leishmania/crescimento & desenvolvimento
[Mh] Termos MeSH secundário: Anfotericina B/farmacologia
Animais
Antiprotozoários/farmacologia
Concentração Inibidora 50
Leishmania/efeitos dos fármacos
Leishmania donovani/crescimento & desenvolvimento
Leishmania major/crescimento & desenvolvimento
Leishmania mexicana/crescimento & desenvolvimento
Metotrexato/farmacologia
Pentamidina/farmacologia
Inoculações Seriadas
Especificidade da Espécie
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amino Acids, Essential); 0 (Antiprotozoal Agents); 0 (Culture Media); 673LC5J4LQ (Pentamidine); 7XU7A7DROE (Amphotericin B); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE


  3 / 13923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29203252
[Au] Autor:Yamazaki H; Kondo T; Aoki K; Yamashita K; Takaori-Kondo A
[Ad] Endereço:Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
[Ti] Título:Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
[So] Source:Diagn Microbiol Infect Dis;90(2):123-131, 2018 Feb.
[Is] ISSN:1879-0070
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Liposomal amphotericin B (L-AMB) has the potential to cause two major adverse events, renal dysfunction and serum potassium abnormality; however, appropriate clinical management of these events remains unclear. We retrospectively analyzed data regarding 128 hematology patients who received L-AMB in our institute and examined the association between clinical characteristics and renal dysfunction or serum potassium abnormality. We found that the median weight-normalized dose of L-AMB was 2.69mg/kg and the median administration period was 16days. The overall occurrence rates of renal dysfunction and hypokalemia were 55.7% and 76.6%, respectively. Multivariate analysis revealed that pre-existing renal dysfunction (P=0.017) and concomitant use of nephrotoxic (P<0.0001) or antifungal drugs (P=0.012) were independent risk factors for renal dysfunction. A higher infusion volume did not mitigate the risk of renal dysfunction. Hypokalemia occurred significantly less often in men (P=0.028) and in patients who concomitantly used nephrotoxic drugs (P=0.013). Approximately 40% of the adverse events were improved at 30days after L-AMB termination and there was no significant association between these adverse events improvement and L-AMB dosage or infusion volume. Of note, hyperkalemia was observed in more patients who received allogeneic hematopoietic stem cell transplantation (P=0.0303) and concomitant treatment with nephrotoxic drugs (P=0.0281). These results suggest that imprudent reduction of L-AMB dose or redundant intravenous infusion may have minimal benefit for critical patients with suspected invasive fungal infection.
[Mh] Termos MeSH primário: Anfotericina B/efeitos adversos
Antifúngicos/efeitos adversos
Hiperpotassemia
Hipopotassemia
Nefropatias
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Anfotericina B/administração & dosagem
Anfotericina B/uso terapêutico
Antifúngicos/administração & dosagem
Antifúngicos/uso terapêutico
Feminino
Doenças Hematológicas/complicações
Seres Humanos
Hiperpotassemia/induzido quimicamente
Hiperpotassemia/epidemiologia
Hiperpotassemia/prevenção & controle
Hipopotassemia/induzido quimicamente
Hipopotassemia/epidemiologia
Hipopotassemia/prevenção & controle
Nefropatias/induzido quimicamente
Nefropatias/epidemiologia
Nefropatias/prevenção & controle
Testes de Função Renal
Masculino
Meia-Idade
Micoses/complicações
Micoses/tratamento farmacológico
Micoses/prevenção & controle
Estudos Retrospectivos
Fatores de Risco
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (liposomal amphotericin B); 7XU7A7DROE (Amphotericin B)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  4 / 13923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29191699
[Au] Autor:Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
[Ad] Endereço:Departamento de Parasitología, ENCB-IPN, 11340 Mexico City, Mexico; Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias-Pediatría, Instituto Mexicano del Seguro Social, 06720 Mexico City, Mexico.
[Ti] Título:In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
[So] Source:Exp Parasitol;184:82-89, 2018 Jan.
[Is] ISSN:1090-2449
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The identification of specific therapeutic targets and the development of new drugs against leishmaniasis are urgently needed, since chemotherapy currently available for its treatment has several problems including many adverse side effects. In an effort to develop new antileishmanial drugs, in the present study a series of 28 N-benzyl-1H-benzimidazol-2-amine derivatives was synthesized and evaluated in vitro against Leishmania mexicana promastigotes. Compounds 7 and 8 with the highest antileishmanial activity (micromolar) and lower cytotoxicity than miltefosine and amphotericin B were selected to evaluate their activity against L. braziliensis 9and L. donovani, species causative of mucocutaneous and visceral leishmaniasis, respectively. Compound 7 showed significantly higher activity against L. braziliensis promastigotes than compound 8 and slightly lower than miltefosine. Compounds 7 and 8 had IC values in the micromolar range against the amastigote of L. mexicana and L. braziliensis. However, both compounds did not show better activity against L. donovani than miltefosine. Compound 8 showed the highest SI against both parasite stages of L. mexicana. In addition, compound 8 inhibited 68.27% the activity of recombinant L. mexicana arginase (LmARG), a therapeutic target for the treatment of leishmaniasis. Docking studies were also performed in order to establish the possible mechanism of action by which this compound exerts its inhibitory effect. Compound 8 shows promising potential for the development of more potent antileishmanial benzimidazole derivatives.
[Mh] Termos MeSH primário: Antiprotozoários/farmacologia
Benzimidazóis/farmacologia
Leishmania braziliensis/efeitos dos fármacos
Leishmania donovani/efeitos dos fármacos
Leishmania mexicana/efeitos dos fármacos
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Anfotericina B/farmacologia
Animais
Antiprotozoários/toxicidade
Arginase/antagonistas & inibidores
Arginase/química
Benzimidazóis/síntese química
Benzimidazóis/química
Benzimidazóis/toxicidade
Linhagem Celular
Concentração Inibidora 50
Leishmania mexicana/enzimologia
Leishmaniose Cutânea/tratamento farmacológico
Leishmaniose Cutânea/parasitologia
Leishmaniose Mucocutânea/tratamento farmacológico
Leishmaniose Mucocutânea/parasitologia
Leishmaniose Visceral/tratamento farmacológico
Leishmaniose Visceral/parasitologia
Macrófagos/efeitos dos fármacos
Camundongos
Simulação de Acoplamento Molecular
Fosforilcolina/análogos & derivados
Fosforilcolina/farmacologia
Alinhamento de Sequência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 0 (Benzimidazoles); 107-73-3 (Phosphorylcholine); 53EY29W7EC (miltefosine); 7XU7A7DROE (Amphotericin B); EC 3.5.3.1 (Arginase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE


  5 / 13923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29253854
[Au] Autor:Abdossamadi Z; Seyed N; Zahedifard F; Taheri T; Taslimi Y; Montakhab-Yeganeh H; Badirzadeh A; Vasei M; Gharibzadeh S; Rafati S
[Ad] Endereço:Department of Immunotherapy and Leishmania Vaccine Research, Pasteur institute of Iran, Tehran, Iran.
[Ti] Título:Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice.
[So] Source:PLoS Negl Trop Dis;11(12):e0006123, 2017 12.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Human Neutrophil Peptide 1 (HNP1) produced by neutrophils, is a well-known antimicrobial peptide which plays a role both in innate as well as in adaptive immunity and is under intensive investigation as a potential therapeutic agent. Previous in vitro experiments have indicated the leishmaniacidal effect of recombinant HNP1 on Leishmania major (L. major) promastigotes and amastigotes. In the current study, we further extended the idea to explore the remedial effect of HNP1 in the two modalities of peptide therapy (folded HNP1) and gene therapy in L. major infected BALB/c mice. To this end, mice in five different groups received synthetic folded HNP1 (G1), pcDNA-HNP1-EGFP (G2), pcDNA-EGFP (G3), Amphotericin B (G4) and PBS (G5), which was started three weeks after infection for three consecutive weeks. Footpad swelling was monitored weekly and a day after the therapy ended, IFN-γ, IL-4, IL-10, IL-6 and nitric oxide produced by splenocytes were analyzed together with the parasite load in draining lymph nodes. Arginase activity and dermal histopathological changes were also analyzed in the infected footpads. We demonstrated that both therapeutic approaches effectively induced Th1 polarization and restricted parasite burden. It can control disease progression in contrast to non-treated groups. However, pcDNA-HNP1-EGFP is more promising in respect to parasite control than folded HNP1, but less effective than AmB treatment. We concluded with the call for a future approach, that is, a DNA-based expression of HNP1 combined with AmB as it can improve the leishmaniacidal efficacy.
[Mh] Termos MeSH primário: Imunoterapia/métodos
Leishmania major/efeitos dos fármacos
Leishmaniose/tratamento farmacológico
Células Th1/imunologia
Tripanossomicidas/uso terapêutico
alfa-Defensinas/uso terapêutico
[Mh] Termos MeSH secundário: Anfotericina B/uso terapêutico
Animais
Arginase/metabolismo
Células COS
Linhagem Celular
Cercopithecus aethiops
Citocinas/sangue
Feminino
Proteínas de Fluorescência Verde/genética
Leishmaniose/parasitologia
Camundongos
Camundongos Endogâmicos BALB C
Óxido Nítrico/metabolismo
Carga Parasitária
Proteínas Recombinantes/genética
Proteínas Recombinantes/uso terapêutico
alfa-Defensinas/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cytokines); 0 (Recombinant Proteins); 0 (Trypanocidal Agents); 0 (alpha-Defensins); 0 (enhanced green fluorescent protein); 0 (human neutrophil peptide 1); 147336-22-9 (Green Fluorescent Proteins); 31C4KY9ESH (Nitric Oxide); 7XU7A7DROE (Amphotericin B); EC 3.5.3.1 (Arginase)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180130
[Lr] Data última revisão:
180130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0006123


  6 / 13923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29186162
[Au] Autor:Efimova SS; Tevyashova AN; Olsufyeva EN; Bykov EE; Ostroumova OS
[Ad] Endereço:Group of Ion Channel Modeling, Institute of Cytology of the Russian Academy of Sciences, St. Petersburg, Russia.
[Ti] Título:Pore-forming activity of new conjugate antibiotics based on amphotericin B.
[So] Source:PLoS One;12(11):e0188573, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A series of amides of the antifungal antibiotic amphotericin B (AmB) and its conjugates with benzoxaboroles was tested to determine whether they form pores in lipid bilayers and to compare their channel characteristics. The tested derivatives produced pores of larger amplitude and shorter lifetime than those of the parent antibiotic. The pore conductance was related to changes in the partial charge of the hydrogens of the hydroxyl groups in the lactone ring that determined the anion coordination in the channel. Neutralization of one of the polar group charges in the AmB head during chemical modification produced a pronounced effect by diminishing the dwell time of the polyene channel compared to modification of both groups. In this study, compounds that had a modification of one carboxyl or amino group were less effective in initializing phase separation in POPC-membranes compared to derivatives that had modifications of both polar groups as well as the parent antibiotic. The effects were attributed to the restriction of the aggregation process by electrical repulsion between charged derivatives in contrast to neutral compounds. The significant correlation between the ability of derivatives to increase the permeability of model membranes-causing the appearance of single channels in lipid bilayers or inducing calcein leakage from unilamellar vesicles-and the minimal inhibitory concentration indicated that the antifungal effect of the conjugates was due to pore formation in the membranes of target cells.
[Mh] Termos MeSH primário: Anfotericina B/farmacologia
Antibacterianos/farmacologia
[Mh] Termos MeSH secundário: Anfotericina B/química
Antibacterianos/química
Fluoresceínas/química
Bicamadas Lipídicas/química
Microscopia de Fluorescência
Fosfatidilcolinas/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Fluoresceins); 0 (Lipid Bilayers); 0 (Phosphatidylcholines); 7XU7A7DROE (Amphotericin B); V0YM2B16TS (fluorexon)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180101
[Lr] Data última revisão:
180101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188573


  7 / 13923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29214974
[Au] Autor:Cavalcante CSP; de Aguiar FLL; Fontenelle ROS; de Menezes RRPPB; Martins AMC; Falcão CB; Andreu D; Rádis-Baptista G
[Ad] Endereço:1​Post-graduate Program in Pharmaceutical Sciences, Federal University of Ceará, 60740-000, Fortaleza, CE, Brazil.
[Ti] Título:Insights into the candidacidal mechanism of Ctn[15-34] - a carboxyl-terminal, crotalicidin-derived peptide related to cathelicidins.
[So] Source:J Med Microbiol;67(1):129-138, 2018 Jan.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Ctn[15-34], a carboxyl-terminal fragment of crotalicidin (a cathelicidin from the venom gland of a South American rattlesnake), has shown antifungal activity against clinical and standard strains of Candida species. The aim of the present work was to investigate the underlying mechanisms of the candidicidal activity of Ctn[15-34]. METHODOLOGY: The time-kill profile and drug synergism were evaluated by means of a microdilution assay and multi-parametric flow cytometry. The presumptive interaction of Ctn[15-34] with lipid membranes was estimated in vitro with a lipid-mimic compound, the chromogenic substance 4-nitro-3-(octanoyloxy)benzoic acid (4N3OBA).Results/Key findings. The absorbance increment (at 425 nm) indicated a concentration- and time-dependent in-solution association between Ctn[15-34] and 4N3OBA. The interaction of Ctn[15-34] with Candida cells was confirmed by flow cytometric measurements with the 5(6)-carboxyfluorescein-labelled peptide (CF-Ctn[15-34]). Analysis of the killing time of Candida exposed to Ctn[15-34] and amphotericin B (AMB) showed that both the peptide and polyene drug reduce the number of c.f.u. but in mechanistically different ways. The Ctn[15-34] peptide alone caused yeast cell membrane disruption, which was confirmed by lactate dehydrogenase leakage and biomarkers of cell death mediated by necrosis. CONCLUSION: Overall, Ctn[15-34] displays a synergistic antifungal activity with AMB, an effect that can be further developed into a multi-target therapeutic option with other antimycotics currently in use.
[Mh] Termos MeSH primário: Antifúngicos/farmacologia
Candida/efeitos dos fármacos
Catelicidinas/farmacologia
Fragmentos de Peptídeos/farmacologia
Peptídeos/farmacologia
[Mh] Termos MeSH secundário: Anfotericina B/farmacologia
Candidíase/tratamento farmacológico
Sinergismo Farmacológico
Fluoresceínas/farmacologia
Seres Humanos
Testes de Sensibilidade Microbiana/métodos
Nitrobenzoatos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (4-nitro-3-(octanoyloxy)benzoic acid); 0 (Antifungal Agents); 0 (Cathelicidins); 0 (Fluoresceins); 0 (Nitrobenzoates); 0 (Peptide Fragments); 0 (Peptides); 0 (crotalicidin); 3301-79-9 (6-carboxyfluorescein); 7XU7A7DROE (Amphotericin B)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171227
[Lr] Data última revisão:
171227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000652


  8 / 13923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29214970
[Au] Autor:Kassi FK; Bellet V; Drakulovski P; Krasteva D; Roger F; Valérie BA; Aboubakar T; Doumbia A; Kouakou GA; Delaporte E; Reynes J; Yavo W; Menan HIE; Bertout S
[Ad] Endereço:1​Laboratoire de Parasitologie et de Mycologie - CeDReS (Centre de Diagnostic et de Recherche sur le SIDA et les Autres Maladies Infectieuses), UFR Pharmacie, CHU de Treichville, Université Félix Houphouët Boigny, Abidjan, Ivory Coast.
[Ti] Título:Comparative typing analyses of clinical and environmental strains of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast.
[So] Source:J Med Microbiol;67(1):87-96, 2018 Jan.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The aim of this study was to assess the biotope of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast, and clarify the possible epidemiological relationship between environmental and clinical strains. METHODOLOGY: Samples from Eucalyptus camaldulensis (n=136), Mangifera indica (n=13) and pigeon droppings (n=518) were collected from different sites close to the living environment of Ivorian HIV patients with cryptococcosis (n=10, 50 clinical strains). Clinical and environmental strains were characterized by molecular serotyping and genotyping [RFLP analysis of the URA5 gene, (GACA)4, (GTG)5 and M13 PCR fingerprinting] and compared.Results/Key findings. Environmental strains were recovered only from the pigeon droppings. In vitro susceptibility profiles showed that all strains were susceptible to fluconazole, flucytosine and amphotericin B. All environmental strains consisted of C. neoformans (A, AFLP1/VNI), whereas clinical strains included C. neoformans (A, AFLP1/VNI), C. neoformans x Cryptococcus deneoformans hybrids (AD, AFLP3/VNIII) and Cryptococcus deuterogattii (B, AFLP6/VGII). Two patients were co-infected with both C. neoformans and C. neoformans x C. deneoformans hybrids. We noticed a low genetic diversity among the environmental samples compared to the high diversity of the clinical samples. Some clinical strains were genetically more similar to environmental strains than to other clinical strains, including those from the same patient. CONCLUSION: These results provide new information on the ecology and epidemiology of the C. neoformans/C. gattii species complex in Ivory Coast.
[Mh] Termos MeSH primário: Cryptococcus gattii/genética
Cryptococcus neoformans/genética
[Mh] Termos MeSH secundário: Adulto
Anfotericina B/uso terapêutico
Antifúngicos/uso terapêutico
Cloranfenicol/uso terapêutico
Costa do Marfim
Criptococose/microbiologia
DNA Fúngico/genética
Microbiologia Ambiental
Feminino
Fluconazol/uso terapêutico
Flucitosina/uso terapêutico
Genótipo
Infecções por HIV/microbiologia
Seres Humanos
Masculino
Testes de Sensibilidade Microbiana/métodos
Meia-Idade
Tipagem Molecular/métodos
Técnicas de Tipagem Micológica/métodos
Estudos Prospectivos
Sorotipagem/métodos
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (DNA, Fungal); 66974FR9Q1 (Chloramphenicol); 7XU7A7DROE (Amphotericin B); 8VZV102JFY (Fluconazole); D83282DT06 (Flucytosine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171227
[Lr] Data última revisão:
171227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000654


  9 / 13923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29240765
[Au] Autor:Ponte-Sucre A; Gamarro F; Dujardin JC; Barrett MP; López-Vélez R; García-Hernández R; Pountain AW; Mwenechanya R; Papadopoulou B
[Ad] Endereço:Department of Physiological Sciences, Laboratory of Molecular Physiology, Institute of Experimental Medicine, Luis Razetti School of Medicine, Universidad Central de Venezuela, Caracas, Venezuela.
[Ti] Título:Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
[So] Source:PLoS Negl Trop Dis;11(12):e0006052, 2017 Dec.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a global basis because treatment failure is an increasing problem. Drug resistance is a fundamental determinant of treatment failure, although other factors also contribute to this phenomenon, including the global HIV/AIDS epidemic with its accompanying impact on the immune system. Pentavalent antimonials have been used successfully worldwide for the treatment of leishmaniasis since the first half of the 20th century, but the last 10 to 20 years have witnessed an increase in clinical resistance, e.g., in North Bihar in India. In this review, we discuss the meaning of "resistance" related to leishmaniasis and discuss its molecular epidemiology, particularly for Leishmania donovani that causes visceral leishmaniasis. We also discuss how resistance can affect drug combination therapies. Molecular mechanisms known to contribute to resistance to antimonials, amphotericin B, and miltefosine are also outlined.
[Mh] Termos MeSH primário: Resistência a Medicamentos
Leishmania/efeitos dos fármacos
Leishmania/patogenicidade
Leishmaniose/tratamento farmacológico
[Mh] Termos MeSH secundário: Anfotericina B/farmacologia
Anfotericina B/uso terapêutico
Antiprotozoários/farmacologia
Antiprotozoários/uso terapêutico
Quimioterapia Combinada
Seres Humanos
Leishmania/genética
Leishmania donovani/efeitos dos fármacos
Leishmania donovani/patogenicidade
Leishmaniose/imunologia
Leishmaniose/parasitologia
Leishmaniose Cutânea/tratamento farmacológico
Leishmaniose Visceral/tratamento farmacológico
Leishmaniose Visceral/parasitologia
Epidemiologia Molecular
Fosforilcolina/análogos & derivados
Fosforilcolina/farmacologia
Fosforilcolina/uso terapêutico
Falha de Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 107-73-3 (Phosphorylcholine); 53EY29W7EC (miltefosine); 7XU7A7DROE (Amphotericin B)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171224
[Lr] Data última revisão:
171224
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0006052


  10 / 13923 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28980793
[Au] Autor:Giovane RA; Manhas P; Gates K
[Ad] Endereço:University of Alabama, Tuscaloosa, AL
[Ti] Título:Itraconazole or Amphotericin B for Talaromycosis.
[So] Source:N Engl J Med;377(14):1402, 2017 10 05.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anfotericina B
Itraconazol
[Mh] Termos MeSH secundário: Antifúngicos
Aspergilose
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Antifungal Agents); 304NUG5GF4 (Itraconazole); 7XU7A7DROE (Amphotericin B)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171011
[Lr] Data última revisão:
171011
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171006
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1709123



página 1 de 1393 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde